Scottsdale-based BioLab Sciences, an emerging regenerative biotechnology company, recently acquired the patents and intellectual property for MyOwn Skin™, a revolutionary regenerative therapy that is transforming the wound care industry, from Bogota, Colombia-based Keraderm. The acquisition enables BioLab Sciences to license MyOwn Skin™ internationally and bring advanced wound care options to patients globally.
“This not only positions us at the forefront of advanced wound care, but, more importantly, will enable us to get this transformative wound coverage to individuals around the world who have been suffering with hard-to-heal wounds,” says Carlos Encinas, Ph.D., chief science officer of BioLab Sciences.
MyOwn Skin™ eliminates the need to surgically remove, or harvest, large areas of healthy skin from other parts of a patient’s body to produce skin grafts, which can often result in an additional wound more painful than the original. This novel biotechnology leverages a very small sample of a patient’s own skin through a non-surgical procedure to reproduce three 4-inch by 4-inch skin grafts within a week, and in some cases accelerate the healing of chronic wounds, diabetic foot ulcers and other difficult-to-heal wounds. Because of its favorable outcomes, MyOwn Skin™ is on track to disrupt the wound care market. In fact, the biotechnology was recently awarded MedTech Outlook Magazine’s Top 10 Wound Care Solution Provider in 2019. And more recently, BioLab was awarded the “Entrepreneur Award: Patient Solution” by Reuter’s Pharma Awards for MyOwn Skin™.
“We’ve been looking for the right partner with experience in the regenerative therapy industry and one that truly prioritizes the health and wellbeing of patients over profits,” said Jorge Soto, CFO of Keraderm. “We found that partner in BioLab Sciences. Plus, they have the network and the right team to bring this important wound care solution to the global market.”
